Cymbalta, a new antidepressant drug expected to get FDA approval this summer, addresses the ailment by attacking two of the brain's chemicals, including norepinephrine, believed by some scientists to be linked to depression. The launch of Eli Lilly's new drug is likely to ignite new debate over whether drugs that seek to attack two chemicals at once are better than those that concentrate on a single source of depression, such as Lilly's own Prozac, a selective serotonin reuptake inhibitor.

Related Summaries